ATXN7L2: A Potential Drug Target for Neurodegenerative Diseases

Target Name: ATXN7L2

NCBI ID: G127002

ATXN7L2

ATXN7L2: A Potential Drug Target for Neurodegenerative Diseases

ATXN7L2 (AT7L2_HUMAN) is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease. The protein is a key component of the huntingtin gene family, which is a family of transmembrane proteins that are involved in a variety of cellular processes, including stress response, neurotransmitter signaling, and cell survival.

ATXN7L2 is a 21-kDa protein that is expressed in the brain and is highly conserved across different species. It is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the prefrontal cortical regions of the brain, as well as in the cerebellum and other brain regions. The protein is involved in the formation of huntingtin nanoparticles, which are thought to play a role in the development of neurodegenerative diseases.

The huntingtin gene family has been implicated in a wide range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurogenic infiltrates. The huntingtin genes are thought to be involved in the production of misfolded proteins, which can cause damage to the brain and contribute to the development of neurodegenerative diseases.

ATXN7L2 has been shown to be involved in the production of huntingtin nanoparticles in neurodegenerative diseases. Studies have shown that the expression of ATXN7L2 is increased in the brains of individuals with Alzheimer's disease, and that the level of huntingtin nanoparticles is increased in the brains of individuals with Parkinson's disease. These findings suggest that ATXN7L2 may be a potential drug target or biomarker for the development and progression of neurodegenerative diseases.

In addition to its involvement in the production of huntingtin nanoparticles, ATXN7L2 is also thought to be involved in the regulation of cellular stress responses. Studies have shown that the expression of ATXN7L2 is increased in response to stress, and that the level of huntingtin nanoparticles is increased in the brains of individuals that are exposed to stress. These findings suggest that ATXN7L2 may be a potential drug target for the treatment of stress-related neurodegenerative diseases.

Overall, the protein ATXN7L2 is a promising candidate for drug targeting or biomarker in the development and progression of neurodegenerative diseases. Further research is needed to fully understand the role of ATXN7L2 in these conditions and to develop effective treatments.

Protein Name: Ataxin 7 Like 2

The "ATXN7L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATXN7L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets